Merck wins ruling on negative SPCs in Europe
The Court of Justice of the EU has ruled that member states can grant negative supplementary protection certificates (SPCs), which will help pharma companies win six-month research extensions
The ruling followed a referral by Germany's Federal Patent Court in a case involving a diabetes drug sold by Merck Sharp & Dohme.
As with other aspects of SPCs, courts around Europe had disagreed on whether a negative SPC was possible....
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.